{"id":"dexamethasone-21-sulfobenzoate-sodium-salt","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The sulfobenzoate ester modification improves aqueous solubility compared to dexamethasone base, allowing for better absorption and distribution. Once absorbed, the ester is hydrolyzed to release active dexamethasone, which binds glucocorticoid receptors to suppress inflammatory cytokine production, reduce immune cell activation, and stabilize cell membranes.","oneSentence":"Dexamethasone-21-sulfobenzoate is a water-soluble prodrug of the corticosteroid dexamethasone that provides enhanced solubility and bioavailability for systemic anti-inflammatory and immunosuppressive effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:38.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders requiring systemic corticosteroid therapy"},{"name":"Acute inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT02953210","phase":"PHASE4","title":"Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2016-11","conditions":"Pain, Postoperative, Anesthesia Complication, Nausea","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexamethasone-21-Sulfobenzoate, Sodium Salt","genericName":"Dexamethasone-21-Sulfobenzoate, Sodium Salt","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone-21-sulfobenzoate is a water-soluble prodrug of the corticosteroid dexamethasone that provides enhanced solubility and bioavailability for systemic anti-inflammatory and immunosuppressive effects. Used for Inflammatory and autoimmune disorders requiring systemic corticosteroid therapy, Acute inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}